1
A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer
Condition(s):Biliary Tract CancerLast Updated:October 12, 2020Recruiting
RC48-ADC: 14 Clinical Trials, Page 1 of 2
Hide Studies Not Open or Pending
2
JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors
Condition(s):HER2-Positive Solid TumorsLast Updated:February 21, 2020Not yet recruiting
3
Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors
Condition(s):Solid TumorsLast Updated:June 4, 2020Completed
4
A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors
Condition(s):Solid TumorsLast Updated:July 30, 2020Completed
5
A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
Condition(s):Urothelial CarcinomaLast Updated:December 17, 2020Active, not recruiting
6
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
Condition(s):Gastric Cancer; HER2 Overexpressing Gastric CarcinomaLast Updated:January 19, 2021Not yet recruiting
7
A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer
Condition(s):Urothelial CarcinomaLast Updated:August 3, 2020Recruiting
8
A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
Condition(s):Urothelial Carcinoma; Advanced CancerLast Updated:August 21, 2019Completed
9
A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer
Condition(s):Urothelial CarcinomaLast Updated:February 13, 2020Recruiting
10
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2
Condition(s):Gastric Cancer; HER2 Overexpressing Gastric CarcinomaLast Updated:June 9, 2020Active, not recruiting